Trial reportFrontiers in medicine2026
Efficacy of oxycodone in managing visceral pain among women undergoing repeat cesarean section: a randomized controlled trial.
Trial report in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The global cesarean section (CS) rate is on the rise, with ratio of repeat CS becoming more common in China following the two-child policy. Postoperative visceral pain, particularly intense in repeat CS parturients and exacerbated by oxytocin, remains inadequately managed. Oxycodone, acting via κ-opioid receptors, has shown promise in relieving visceral pain, but its efficacy in repeat CS populations is unclear, which was explored in this study. Methods: This randomized controlled trial enrolled 100 parturients undergoing elective repeat CS, randomized to patient-controlled intravenous analgesia (PCIA) with oxycodone (50 mg/100 ml) or sufentanil (100 μg/100 ml). Primary outcomes were maximum visceral pain Numerical Rating Scale (NRS) scores during 0-24 h postoperatively. Secondary outcomes included visceral pain NRS during oxytocin administration on postoperative days 1-2, postoperative inflammatory markers (neutrophil-to-lymphocyte ratio, NLR), time to autonomic activity and PCIA presses. This trial was registered with the Chinese Clinical Trial Registry (ChiCTR2400087624; July 31 2024). Results: Significantly lower maximum visceral pain NRS scores in the oxycodone group during 24h after surgery compared to sufentanil group (2.2 ± 0.6 Conclusion: In conclusion, oxycodone effectively alleviates postoperative visceral pain and mitigates inflammatory responses in repeat CS parturients, making it a preferred choice for postoperative analgesia in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.